Jessy Palathinkal
Gerontology · Philadelphia, PANPI 1851945935
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 185 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by GSK at 26.1% of the total. Reporting peaked in 2023 at $1,076 and has fallen 91.7% since, to $90 in 2025. Among gerontology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$921
- AbbVie$468
- Astellas Pharma US Inc$325
- Bayer$244
- Lilly USA, LLC$207
- AstraZeneca$199
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,31694%
- Education$2146%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 48 | $921 |
| AbbVie(2 entities) | 28 | $468 |
| Astellas Pharma US Inc | 11 | $325 |
| Bayer | 15 | $244 |
| Lilly USA, LLC | 11 | $207 |
| AstraZeneca | 11 | $199 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $154 |
| Novo Nordisk | 7 | $149 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $128 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Pfizer | 4 | $107 |
| Sanofi-aventis U.S. LLC | 4 | $91 |
| Novartis | 5 | $83 |
| Biohaven Pharmaceuticals, Inc. | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Exact Sciences | 2 | $51 |
| Johnson & Johnson | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
How this compares
$3,530 in reported general payments places this provider in the 90th percentile of 383 gerontology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 142 | $138,707 |
| FarxigaDapagliflozin Propanediol | 140 | $97,816 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $48,493 |
| JardianceEmpagliflozin | 56 | $39,076 |
| JanuviaSitagliptin Phosphate | 54 | $33,703 |
| OzempicSemaglutide | 26 | $31,739 |
| EliquisApixaban | 46 | $29,369 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $17,634 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 152 | $13,571 |
| MyrbetriqMirabegron | 15 | $12,700 |
| XareltoRivaroxaban | 19 | $12,528 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 416 | $11,055 |
| KerendiaFinerenone | 16 | $9,582 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,041 |
| Humalog Kwikpen U-100Insulin Lispro | 49 | $7,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $207 | $138,707142 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $199 | $118,186173 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $921 | $56,53390 claims |
| Boehringer IngelheimJardiance | $21 | $39,07656 claims |
| Novo NordiskOzempic | $149 | $31,73926 claims |
| PfizerEliquis | $107 | $29,36946 claims |
| Astellas Pharma US IncMyrbetriq | $325 | $12,70015 claims |
| Johnson & JohnsonXarelto | $42 | $12,52819 claims |
| BayerKerendia | $244 | $9,58216 claims |
| AbbVieLinzess | $468 | $7,13514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 383 gerontology providers in Pennsylvania.
Other gerontology in Philadelphia
- Maria BonanniPhiladelphia$36K
- Alanna MillerPhiladelphia$9K
- Mary KelleyPhiladelphia$8K
- Yana YazmirPhiladelphia$6K
- Denise MillerPhiladelphia$5K
- Jacquelyn LevinPhiladelphia$4K
- Olivia CarrasquilloPhiladelphia$3K
- Carol GungPhiladelphia$3K
- Larena RobinsonPhiladelphia$3K
- Kimberly LeottaPhiladelphia$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.